Demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) and control subjects. Except where indicated otherwise, values are the number (%) of subjects. Disease duration was calculated since the first non-Raynaud’s symptom and did not differ significantly among subsets of patients with SSc.
| Characteristics | Patients with SSc, n = 250 | Controls, n = 263 |
|---|---|---|
| Mean age, yrs ± SD | 55.9 ± 12.5 | 54.5 ± 12.7 |
| Sex | ||
| Male | 27 (10.8) | 46 (17.5) |
| Female | 223 (89.2) | 217 (82.5) |
| Mean disease duration, yrs ± SD | 7.7 ± 6.9 | — |
| Disease subset | ||
| lcSSc | 146 (58.4) | — |
| dcSSc | 104 (41.6) | — |
| Autoantibody positivity | ||
| ANA | 227 (90.8) | — |
| Anti-topo I | 77 (30.8) | — |
| ACA | 91 (36.4) | — |
| Organ involvement | ||
| ILD | 74 (29.6) | — |
| PAH | 35 (14.0) | — |
ACA: anticentromere antibodies; ANA: antinuclear antibodies; anti-topo I: antitopoisomerase I antibodies; dcSSc: diffuse cutaneous SSc; ILD: interstitial lung disease; lcSSc: limited cutaneous SSc; PAH: pulmonary arterial hypertension.